Novartis India
NOVARTIND · Retail > Trading · Chairman: C Snook · MD: Sanjay Murdeshwar · Listing date: Nov. 9, 2000 · Employees: 539 · Mumbai · http://www.novartis.in

Stock Price vs Company Growth
1d
0.8%
1w
2.1%
1m
7.8%
3m
15.2%
6m
20.0%
1y
23.3%
5y
6.9%
all
5.6%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 791 0.8%
785
942
Company Overview

Sales
355 Cr
Growth: 0.2%
Profit after Tax
107 Cr
Growth: 3.7%
Small Cap
1,953 Cr
P/E: 18.3x
Industry P/E: 29.2x
Fundamentals

Sales (Cr) ₹ 355
Growth 0.2%
EBITDA 28.4%
P/S 5.5x
Dividend 2.1%
P/E 18.3x
Book Value ₹ 339
PEG Ratio 89.1x
ROE 13.1%
P/B 2.4x
Shareholding Pattern

Institutions
Promoters
Novartis Ag
70.68 %
Others
Atul Limited
1.52 %
Iepf
0.47 %
Llp, Partnership Firm, Directors' Relative
0.14 %
Increase    Decrease    No change
Company Profile Detailed

As a science-based and patient-oriented healthcare company, it strives to be a global leader in growing areas of healthcare. Following a corporate transformation Novartis globally is focused on three divisions with global scale and innovation power - pharmaceuticals, eye care and generic medicines. This has strengthened the future growth prospects of the company.
Investors (7)
Followers (1)